First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma‑2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer

Pancreatic cancer, with its increasing
incidence and lowest 5-year
survival rate, is predicted to become the second leading cause of
cancer deaths by 2030. Current clinical trials have shown limited
improvement, highlighting the need for new therapies. The sigma-2
receptor (S2R), with roles in tumor progression, is a target for novel
thiosemicarbazones (TSCs). FA4 has shown potent activity
against pancreatic cancer in vivo. We synthesized
complexes of FA4 with Cu(II) and Pt(II), and compared
their efficacy with complexes of the non-S2R-targeting TSC 1. TSC-Cu exhibited over 50-fold higher in vitro cytotoxicity
than TSCs-Pt, which was less active than TSCs. FA4-Cu
induced apoptotic cell death via ER and mitochondrial
stress showing more potent activity than FA4. This in vitro effect was replicated in the preclinical PANC-1
model, where FA4-Cu was more potent than FA4, 1, and 1-Cu. These results support further
exploration of FA4-Cu as a potential therapy for pancreatic
cancer.